-
31
Jan
23
-
KemPharm Enhances Senior Management Team
-
News & Publications
KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.
-
24
Jan
23
-
KemPharm Issues Letter to Shareholders
-
-
18
Jan
23
-
KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
-
-
11
Jan
23
-
KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
-
-
09
Jan
23
-
KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company
-
-
21
Dec
22
-
KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)
-
-
29
Nov
22
-
KemPharm Announces Appointment of Christopher Posner as New Independent Director
-
-
18
Nov
22
-
KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)
-
-
09
Nov
22
-
KemPharm Reports Third Quarter 2022 Results
-
-
01
Nov
22
-
KemPharm to Report Third Quarter 2022 Financial Results
-
-
04
Oct
22
-
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th
-
-
28
Sep
22
-
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)
-